Sarah Bennett
Respiratory Syncytial Virus (RSV) is a highly contagious condition that causes mild cold symptoms in most people but can lead to severe illness, hospitalization, and even death in older people and babies. RSV is one of the leading causes of hospitalization in young babies, with up to 80,000 babies hospitalized with RSV each year in the US. Fortunately, there are effective immunizations to protect against RSV, including vaccines for pregnant women and infants. The CDC recommends that all babies be protected from severe RSV by either a maternal RSV vaccine or an RSV antibody given to the baby. This paragraph will explore the topic of RSV vaccines and their effectiveness in preventing RSV in babies.
| Characteristics | Values |
|---|---|
| Recommended immunization options | A maternal RSV vaccine given to the mother during pregnancy (weeks 32-36) or an RSV antibody given to the baby |
| Maternal vaccine | Pfizer's Abrysvo |
| Maternal antibodies protection duration | Approximately 6 months after birth |
| Long-acting infant RSV antibodies | Nirsevimab or Clesrovimab |
| Infant antibodies protection duration | At least 5 months |
| Infant antibodies side effects | Pain, redness, swelling, mild rash |
| Infant antibodies efficacy | 79.0% in preventing RSV-associated lower respiratory tract infection (LRTI) and 80.6% in preventing RSV-associated LRTI with hospitalization |
| Infant antibodies administration time | Shortly before the RSV season or within 1 week after birth if born during October-March |
| Infant antibodies administration method | Injection into the deltoid muscle in the upper arm |
Explore related products
What You'll Learn
The maternal RSV vaccine
Pregnant women who are more than 36 weeks and six days pregnant should not be vaccinated, as there may not be enough time for the antibodies to develop and protect the infant. In such cases, the infant should receive RSV immunization just before or at the start of the RSV season. The CDC does not recommend maternal vaccination outside of the September to January period in most of the U.S. because it would provide limited protection to the infant during the RSV season.
Interstate Travel in Australia: Vaccination Requirements for Flying
You may want to see also
Explore related products
RSV antibodies for infants
The CDC recommends that all babies be protected from severe RSV by one of two immunisation options: a maternal RSV vaccine or an RSV antibody given to the baby. Most babies won't need both. The maternal RSV vaccine (Pfizer's Abrysvo) is given during weeks 32–36 of pregnancy. Maternal antibodies protect the baby against RSV for about six months after birth.
Two long-acting RSV antibodies are available for infants: nirsevimab and clesrovimab. An infant RSV antibody dose should be given to babies shortly before the RSV season, or within one week after birth if born during October through March. Nirsevimab is also recommended for a small group of young children aged 8–19 months who are at increased risk of severe RSV. Clesrovimab is not recommended for this age group.
Infant RSV antibodies are highly effective in preventing RSV-associated hospitalisation. Side effects are usually mild, such as pain, redness, or swelling where the injection was given, and they resolve quickly. Hypersensitivity reactions are uncommon but have been reported with similar antibody products.
In clinical studies among infants who were born during or entering their first RSV season, efficacy for preventing RSV-associated LRTI with hospitalisation was 90.9% through 150 days. Early real-world data show that nirsevimab was at least 70% effective in preventing babies from being hospitalised with RSV.
AstraZeneca's COVID-19 Vaccine: What You Need to Know
You may want to see also
Explore related products
Timing of administration
The timing of administration of the RSV vaccine depends on whether the recipient is a pregnant mother or an infant.
The CDC recommends that pregnant mothers receive the RSV vaccine during weeks 32-36 of pregnancy. This timing ensures that the mother's antibodies are passed on to the baby, protecting them from birth until they are approximately six months old, which is when they are at the highest risk of severe RSV.
The CDC recommends that infants receive an RSV antibody dose shortly before the RSV season or within one week of birth if born during October through March in most of the U.S. This recommendation applies to infants born to mothers who did not receive the maternal RSV vaccine during pregnancy.
The RSV season typically peaks between December and January, so it is important for infants to have protection before this period. The antibodies can be administered during any visit to a healthcare setting, including well-child visits or during birth hospitalization.
The optimal timing for infant RSV antibody administration is during October or November, or within the first week of life for babies born between October and March. This ensures protection during the RSV season, which usually lasts about five months.
For infants eligible for RSV antibody treatment with prolonged hospitalizations shortly before or during the RSV season, healthcare providers may administer the antibody during the hospitalization to prevent healthcare-associated RSV disease. This decision should be based on clinical judgment, weighing the potential risks and benefits.
Vaccine Safety Testing: Are We Doing Enough?
You may want to see also
Explore related products
RSV season
RSV, or Respiratory Syncytial Virus, is a seasonal virus that typically peaks between December and January. RSV is a highly contagious virus that can cause severe respiratory illness in babies and young children. The virus spreads through tiny droplets in the air when an infected person coughs or sneezes. It can also spread through direct contact with contaminated surfaces.
The RSV season typically starts in the fall, with the number of cases rising steadily until it peaks in the winter months. The exact timing of the RSV season can vary from year to year, and it may start earlier or later depending on various factors, including the prevalence of other respiratory viruses, such as the flu, and the impact of preventive measures such as masking and social distancing.
The 2020-2021 RSV season was significantly impacted by the COVID-19 pandemic and the associated isolation and masking measures. The reduced spread of respiratory viruses during this period led to a lower-than-usual number of RSV cases in 2020. However, in 2021, there was a surge in RSV cases, with the season starting earlier than usual and peaking in October-November. The 2022-2023 season followed a similar pattern, with an earlier peak in November and a higher hospitalization rate.
Experts predict that the 2025-2026 RSV season will likely have a similar hospitalization rate to the previous season, with a peak occurring during the fall and winter months. To prepare for the upcoming RSV season, the CDC recommends preventive measures such as vaccination and basic hygiene practices, including handwashing, covering coughs and sneezes, and wearing masks in crowded spaces when RSV rates are high.
To protect infants from RSV during the seasonal surge, the CDC recommends two immunization options: a maternal RSV vaccine (Pfizer's Abrysvo) administered during weeks 32-36 of pregnancy or a long-acting infant RSV antibody (nirsevimab or clesrovimab) given shortly before the RSV season or within the first week of life for babies born during the RSV season. These preventive measures can significantly reduce the risk of severe RSV disease in infants and young children.
Travel Freedoms: Vaccines or No Jab, Can You Fly?
You may want to see also
Explore related products
Side effects
The RSV vaccine helps protect against infection with RSV, a common respiratory virus that can cause mild, cold-like symptoms. RSV usually gets better by itself, but it can cause serious breathing problems in babies and older adults, sometimes requiring hospitalisation. To prevent severe RSV disease in infants, maternal RSV vaccination or infant immunisation with a long-acting RSV monoclonal antibody is recommended.
The side effects of the RSV vaccine in babies are typically mild and may include:
- Injection site reactions: redness, pain, swelling, or rash at the injection site. These reactions are usually mild and last only a few days.
- Fever: this has been reported with Synagis and can also occur in babies and young children receiving RSV immunisations.
- Fatigue: this is a common side effect of the RSV vaccine and can make babies and young children feel tired and lethargic.
- Muscle and joint pain: these are common side effects, but the pain is usually mild and can be treated with ice packs or over-the-counter pain relievers.
- Nausea: this is another common side effect, especially during pregnancy, and can cause stomach discomfort and vomiting.
- Diarrhea: this may occur as a reaction to the vaccine and can cause loose or watery stools.
It is important to note that the side effects of the RSV vaccine in babies are typically mild and resolve quickly. However, if any side effects seem to be getting worse or persist for an extended period, it is important to contact your healthcare provider for further guidance and support.
RSV Vaccine Coverage: Does Medicare Part B Pay?
You may want to see also
Frequently asked questions
The maternal RSV vaccine teaches the mother's immune system to fight the disease, and this protection is passed on to the baby. The antibodies protect the baby for approximately 6 months after birth.
Common side effects of the RSV vaccine include injection site reactions, fatigue, headache, muscle and joint pain, nausea, diarrhoea, fever, and underarm swelling. These side effects are typically mild and can be managed at home.
The RSV vaccine has been shown to be around 80% effective in preventing RSV-related hospitalisations. In clinical trials, a single dose of the vaccine given during pregnancy reduced the risk of an RSV infection leading to infant hospitalisation during the first six months of life in 5 or 6 out of every 10 infants born to vaccinated individuals.
